Form 4: M33 Growth Entities Divest $20.7M in Oncology Institute Stock

M33 Growth I L.P. and related entities, identified as 10% owners and directors, sold 6.7 million shares of Oncology Institute, Inc. common stock for $3.09 per share.

Summary

• M33 Growth I L.P., M33 Growth I GP LLC, and TOI M, LLC reported a sale of common stock in Oncology Institute, Inc. (TOI).
• The transactions occurred on September 4, 2025.
• M33 Growth I L.P. directly disposed of 6,018,168 shares of common stock.
• TOI M, LLC indirectly disposed of 681,832 shares of common stock.
• All shares were sold at a price of $3.09 per share.
• Following these transactions, M33 Growth I L.P. directly beneficially owns 7,932,389 shares.
• TOI M, LLC indirectly beneficially owns 590,892 shares.
• M33 Growth I GP LLC is the general partner of M33 Growth I L.P. and may be deemed to beneficially own shares held by M33 LP, disclaiming beneficial ownership except to the extent of its pecuniary interest.
• All reporting persons are identified as both a Director and a 10% Owner of Oncology Institute, Inc.

Sentiment

Score: 3

Explanation: A significant sale by a major institutional investor and director-affiliated entities typically generates negative sentiment, as it can be perceived as a lack of confidence in the company's future prospects or valuation.

Positives

• The sale occurred at a specific price of $3.09 per share, indicating a market for the shares at that valuation on the transaction date.

Negatives

• A significant reduction in beneficial ownership by a major institutional investor and director-affiliated entities.
• The sale of 6,700,000 shares by entities associated with a director and 10% owner could be interpreted as a signal of reduced confidence or a strategic portfolio rebalancing.
• The total value of shares sold is approximately $20,703,000, representing a substantial divestment.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The sale of common stock by M33 Growth I L.P. and TOI M, LLC, both identified as 10% owners and affiliated with a director of Oncology Institute, Inc., constitutes a related party transaction.
• M33 Growth I GP LLC, the general partner of M33 Growth I L.P., is also a reporting person and may be deemed to beneficially own shares held by M33 LP, further linking the entities involved in the transaction.

Stakeholder Impact

• Shareholders may interpret the significant sale by a major institutional investor and director-affiliated entities as a negative signal regarding the company's future prospects or current valuation.
• The large volume of shares sold could potentially contribute to increased selling pressure on the stock in the short term.

Key Dates

Keywords

Oncology Institute, TOI, M33 Growth, Insider Sale, Form 4, Beneficial Ownership, Stock Transaction, Director Sale, 10% Owner